The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.
- Tablets, enteric coated 250 mg
Interferes with microbial protein synthesis.
Rapidly absorbed and converted by nonenzymatic hydrolysis to erythromycylamine (active). For erythromycylamine, the C max is approximately 0.3 to 0.4 mcg/mL. T max approximately 3.9 to 4.1 h. AUC approximately 0.9 to 1.8 mcg•h/mL.
For erythromycylamine, the protein binding is 15% to 30% and the Vd is 800 L.
81% to 97% excreted in the feces and approximately 2% eliminated through the kidneys. For erythromycylamine, the plasma t ½ is approximately 8 h, the terminal t ½ is approximately 44 h, and the Cl is approximately 23 L/h.
Special PopulationsRenal Function Impairment
C max and AUC are increased. No dosage adjustment necessary.Hepatic Function Impairment
In those with mild hepatic impairment, the C max , AUC, and Vd are increased. No dosage adjustment necessary.Elderly
C max and AUC increase with age. No dosage adjustment necessary.
Indications and Usage
Treatment of acute bacterial infection of chronic bronchitis, secondary bacterial infection of acute bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections caused by susceptible organisms.
Hypersensitivity to erythromycin or any macrolide antibiotic.
Dosage and AdministrationAdults and Children 12 yr of age and older
PO 500 mg once daily for 7 to 14 days.
Store at room temperature.
Since cardiotoxicity and death have occurred with other macrolide antibiotics, monitor patient during concurrent use; however, available clinical data indicate that there is no interaction.Theophylline
Slight decrease in theophylline serum concentrations may occur.
Laboratory Test Interactions
None well documented.
Headache; dizziness; vertigo; insomnia.
Rash; pruritus; urticaria.
Abdominal pain; nausea; diarrhea; vomiting; dyspepsia; flatulence.
Increased platelet count; eosinophilia; increased segmented neutrophils.
Increased cough; shortness of breath.
Increased serum potassium; pain; weakness; increased CPK.
Category C .
Safety and efficacy in children younger than 12 yr of age not established.
Prolonged use of antibiotics may result in bacterial or fungal overgrowth of nonsusceptible microorganisms.
Consider possibility in patients who develop diarrhea.
Nausea, vomiting, epigastric distress, diarrhea.
- Instruct patient to take medication with food or within 1 h after meals.
- Instruct patient to notify healthcare provider if rash develops or difficulty breathing occurs.
- Stress to patient that entire course of therapy must be completed, and not to stop taking medication when feeling better.
- Warn patient that if infection does not seem to improve after 5 days, to notify healthcare provider.
- Instruct patient to drink 2 to 3 liters of fluid per day while taking oral antibiotics.
Copyright © 2009 Wolters Kluwer Health.